Daily Oral Medication

Overweight (BMI 25 to 29.9) with at least one weight-related risk factor

Locations: Long Island City, Queens (36-36 33rd Street)

Cost to you: none for study visits, tests, or study medication

Questions: 516-574-9232 · Hablamos español

A Phase 3, randomized, double-blind, placebo-controlled study of a once-daily oral investigational medication in adults with overweight who are at risk of obesity-related complications or of progressing to class 1 obesity.
- At least 18 years of age
- BMI of 25 to 29.9
- Waist-to-height ratio of 0.5 or more
- At least one of the following: prediabetes (HbA1c 5.7% to 6.4% or fasting glucose 100 to 125 mg/dL); prehypertension or high-normal blood pressure on two separate occasions if untreated (systolic 120 to 139 or diastolic 80 to 89); or predyslipidemia (fasting LDL-C 130 to 159 mg/dL, triglycerides 150 to 199 mg/dL, or total cholesterol 200 to 239 mg/dL)
- At least one self-reported unsuccessful attempt to lose weight through diet and exercise
Gain access to cutting-edge medications and treatments before they are widely available.
Our expert team is under the guidance of renowned endocrinologist, Dr. Anastasios Manessis.
We are highly focused on patient well-being and the highest ethical standards in clinical research.